Skip to content

Efficacy and Safety of Remimazolam for Sedation During Hysteroscopy

Efficacy and Safety of Remimazolam for Sedation During Hysteroscopy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092598
Enrollment
Unknown
Registered
2024-11-19
Start date
2025-02-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopy

Interventions

Remimazolam group:Sedation based on remimazolam
Propofol group:Sedation based on propofol

Sponsors

Enze Hospital, Taizhou Enze Medical Center (Group)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1.All women scheduled to receive hysteroscopy under sedation;

Exclusion criteria

Exclusion criteria: 1.ASA grade III or above; 2.Age =65 years or <18 years; 3.BMI =30kg/m2 or BMI <18kg/m2; 4.Presence of liver or kidney dysfunction before surgery; 5.History of upper respiratory tract infection in the past week; 6.History of alcohol abuse; 7.Allergy to benzodiazepines, opioids, or flumazenil; 8.Auditory or visual impairment that prevents normal communication; 9.Coexisting mental illness; 10.Pregnant or lactating women; 11.Refusal to participate in the trial;

Design outcomes

Primary

MeasureTime frame
Success rate of sedation;First dose sedation success rate;

Secondary

MeasureTime frame
Hypotension;Hypoxemia;Injection pain;Bradycardia;Recovery time;Induction time;Body movement;

Countries

China

Contacts

Public ContactRui Lu

Enze Hospital, Taizhou Enze Medical Center (Group)

lur0805@enzemed.com+86 18268017945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026